ESMO-EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease

被引：22
作者：
Bossi, P. [1 ]
Chan, A. T. [2 ]
Even, C. [3 ]
Machiels, J. -P. [4 ,5 ]
机构：
[1] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, ASST Spedali Civili, Brescia, Italy
[2] Chinese Univ Hong Kong, State Key Lab Translat Oncol, Shatin, Hong Kong, Peoples R China
[3] Gustave Roussy, Head & Neck Dept, Paris, France
[4] Clin Univ St Luc, Inst Roi Albert II, Serv Oncol Med, Brussels, Belgium
[5] Catholic Univ Louvain, Inst Rech Clin & Expt POLE MIRO, Brussels, Belgium
[6] ESMO Guidelines Comm, ESMO Head Off, Via Ginevra 4, CH-6900 Lugano, Switzerland
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷 / 03期
关键词：
nasopharyngeal carcinoma; Clinical Practice Guideline; capecitabine; adjuvant; immunotherapy; recurrent and/or metastatic;
D O I：
10.1016/j.annonc.2022.11.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：247 / 250
页数：4
相关论文
共 6 条
[1]   Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Bossi, P. ;
Chan, A. T. ;
Licitra, L. ;
Trama, A. ;
Orlandi, E. ;
Hui, E. P. ;
Halamkova, J. ;
Mattheis, S. ;
Baujat, B. ;
Hardillo, J. ;
Smeele, L. ;
van Herpen, C. ;
Castro, A. ;
Machiels, J-P .
ANNALS OF ONCOLOGY, 2021, 32 (04) :452-465
[2]   Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial [J].
Chen, Yu-Pei ;
Liu, Xu ;
Zhou, Qin ;
Yang, Kun-Yu ;
Jin, Feng ;
Zhu, Xiao-Dong ;
Shi, Mei ;
Hu, Guo-Qing ;
Hu, Wei-Han ;
Sun, Yan ;
Wu, Hong-Fen ;
Wu, Hui ;
Lin, Qin ;
Wang, Hui ;
Tian, Ye ;
Zhang, Ning ;
Wang, Xi-Cheng ;
Shen, Liang-Fang ;
Liu, Zheng-Zheng ;
Huang, Jing ;
Luo, Xiu-Ling ;
Li, Ling ;
Zang, Jian ;
Mei, Qi ;
Zheng, Bao-Min ;
Yue, Dan ;
Xu, Jing ;
Wu, San-Gang ;
Shi, Yan-Xia ;
Mao, Yan-Ping ;
Chen, Lei ;
Li, Wen-Fei ;
Zhou, Guan-Qun ;
Sun, Rui ;
Guo, Rui ;
Zhang, Yuan ;
Xu, Cheng ;
Lv, Jia-Wei ;
Guo, Ying ;
Feng, Hui-Xia ;
Tang, Ling-Long ;
Xie, Fang-Yun ;
Sun, Ying ;
Ma, Jun .
LANCET, 2021, 398 (10297) :303-313
[3]   ESMO-Magnitude of Clinical Benefit Scale version 1.1 [J].
Cherny, N. I. ;
Dafni, U. ;
Bogaerts, J. ;
Latino, N. J. ;
Pentheroudakis, G. ;
Douillard, J. -Y. ;
Tabernero, J. ;
Zielinski, C. ;
Piccart, M. J. ;
de Vries, E. G. E. .
ANNALS OF ONCOLOGY, 2017, 28 (10) :2340-2366
[4]   Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial [J].
Mai, Hai-Qiang ;
Chen, Qiu-Yan ;
Chen, Dongping ;
Hu, Chaosu ;
Yang, Kunyu ;
Wen, Jiyu ;
Li, Jingao ;
Shi, Ying-Rui ;
Jin, Feng ;
Xu, Ruilian ;
Pan, Jianji ;
Qu, Shenhong ;
Li, Ping ;
Hu, Chunhong ;
Liu, Yi-Chun ;
Jiang, Yi ;
He, Xia ;
Wang, Hung-Ming ;
Lim, Wan-Teck ;
Liao, Wangjun ;
He, Xiaohui ;
Chen, Xiaozhong ;
Liu, Zhigang ;
Yuan, Xianglin ;
Li, Qi ;
Lin, Xiaoyan ;
Jing, Shanghua ;
Chen, Yanju ;
Lu, Yin ;
Hsieh, Ching-Yun ;
Yang, Muh-Hwa ;
Yen, Chia-Jui ;
Samol, Jens ;
Feng, Hui ;
Yao, Sheng ;
Keegan, Patricia ;
Xu, Rui-Hua .
NATURE MEDICINE, 2021, 27 (09) :1536-+
[5]  
Miao J, 2022, JAMA ONCOL
[6]   Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial [J].
Yang, Yunpeng ;
Qu, Song ;
Li, Jingao ;
Hu, Chaosu ;
Xu, Mingjun ;
Li, Weidong ;
Zhou, Ting ;
Shen, Liangfang ;
Wu, Hui ;
Lang, Jinyi ;
Hu, Guangyuan ;
Luo, Zhanxiong ;
Fu, Zhichao ;
Qu, Shenhong ;
Feng, Weineng ;
Chen, Xiaozhong ;
Lin, Shaojun ;
Zhang, Weimin ;
Li, Xiaojiang ;
Sun, Yan ;
Lin, Zhixiong ;
Lin, Qin ;
Lei, Feng ;
Long, Jianting ;
Hong, Jinsheng ;
Huang, Xiaoming ;
Zeng, Lingzhi ;
Wang, Peiguo ;
He, Xiaohui ;
Zhang, Ben ;
Yang, Qing ;
Zhang, Xiaojing ;
Zou, Jianjun ;
Fang, Wenfeng ;
Zhang, Li .
LANCET ONCOLOGY, 2021, 22 (08) :1162-1174
1